Abstract
Antitumoral synthetic vaccines offer a promising alternative to overcome problems associated with traditional treatments. Numerous vaccine prototypes have been described in the last two decades; however, none of them have been revealed satisfactory in clinical trials due to side effects, low bioavailability, uncertain molecular composition, and/or reproducibility. Here we highlight major advances in carbohydrate-based vaccines, which open new perspectives in cancer immunotherapy.